FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

DreaMed Diabetes Gets CE Mark for Diabetes Management Platform

Feb. 16, 2018

Israel-based devicemaker DreaMed Diabetes obtained a CE Mark for its Advisor Pro decision-support platform to aid clinicians’ management of Type 1 diabetes.

The cloud-based smart decision software uses the company’s proprietary machine learning algorithms to process and analyze data collected from insulin pumps, continuous glucose monitors, among other connected medical devices, as well as food consumption data.

The analyses can be used to identify personalized insulin doses. The product is “the only diabetes decision support solution that has received regulatory approval for optimizing insulin pump therapy using continuous glucose monitoring data,” the company said.

View today's stories